Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Flower pollen extract** is a standardized botanical drug product derived primarily from grass pollens including rye grass, corn, and timothy grass, most commonly formulated as the Graminex pollen extract mixture containing pollen-pistil extract PI 82 and purified pollen extract GC FEM. It has been developed and marketed as a phytotherapeutic oral product for chronic prostatitis chronic pelvic pain syndrome and benign prostatic hyperplasia, with additional use in menopausal and premenstrual symptom management. The exact molecular target is not well defined; available preclinical and clinical literature supports a multimodal anti-inflammatory and anti-proliferative pharmacology, and reports indicate lack of meaningful estrogenic activity in products used for menopausal symptoms. Overall, it is best characterized as a botanical small-molecule complex or nutraceutical-like phytotherapeutic with a favorable safety profile and symptomatic benefit rather than a single-target pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flower pollen extract.